A Detailed Analysis of the Catheter Associated Urinary Tract Infections (CAUTIs) Treatment Market Based on the Increased Prevalence of Chronic Illnesses, and CAUTI Cases
Industry: Healthcare
Published Date: January-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 216
Report ID: PMRREP33711
1. Executive Summary
1.1. Global Catheter-Associated Urinary Tract Infections Treatment Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Drug Type Lifecycle Analysis
2.4. Catheter-Associated Urinary Tract Infections Treatment Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Distribution Channels
2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape
3. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2013-2016
3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Drug Type
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug Type, 2018 - 2022
3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
3.3.3.1. Penicillin & Combinations
3.3.3.2. Quinolones
3.3.3.3. Cephalosporin
3.3.3.4. Aminoglycoside Antibiotics
3.3.3.5. Sulphonamides
3.3.3.6. Azoles and Amphotericin B
3.3.3.7. Tetracycline
3.3.3.8. Nitrofurans
3.3.3.9. Other
3.4. Market Attractiveness Analysis: Drug Type
3.5. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Indication Type
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Indication Type, 2018 - 2022
3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
3.5.3.1. Asymptomatic CAUTI (Bacteriuria)
3.5.3.2. Symptomatic CAUTI (Bacteremic)
3.6. Market Attractiveness Analysis: Indication Type
3.7. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Distribution Channel
3.7.1. Introduction / Key Findings
3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Distribution Channel, 2018 - 2022
3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
3.7.3.1. Hospital Pharmacies
3.7.3.2. Gynaecology and Urology Clinics
3.7.3.3. Drug Stores
3.7.3.4. Retail Pharmacies
3.7.3.5. Online Drug Stores
3.8. Market Attractiveness Analysis: Distribution Channel
4. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia & Pacific
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
5.3.1. By Country
5.3.2. By Drug Type
5.3.3. By Indication Type
5.3.4. By Distribution Channel
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
5.5.1. Penicillin & Combinations
5.5.2. Quinolones
5.5.3. Cephalosporin
5.5.4. Aminoglycoside Antibiotics
5.5.5. Sulphonamides
5.5.6. Azoles and Amphotericin B
5.5.7. Tetracycline
5.5.8. Nitrofurans
5.5.9. Other
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
5.6.1. Asymptomatic CAUTI (Bacteriuria)
5.6.2. Symptomatic CAUTI (Bacteremic)
5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
5.7.1. Hospital Pharmacies
5.7.2. Gynaecology and Urology Clinics
5.7.3. Drug Stores
5.7.4. Retail Pharmacies
5.7.5. Online Drug Stores
5.8. Market Attractiveness Analysis
6. Europe Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Drug Type
6.3.3. By Indication Type
6.3.4. By Distribution Channel
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Turkey
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
6.5.1. Penicillin & Combinations
6.5.2. Quinolones
6.5.3. Cephalosporin
6.5.4. Aminoglycoside Antibiotics
6.5.5. Sulphonamides
6.5.6. Azoles and Amphotericin B
6.5.7. Tetracycline
6.5.8. Nitrofurans
6.5.9. Other
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
6.6.1. Asymptomatic CAUTI (Bacteriuria)
6.6.2. Symptomatic CAUTI (Bacteremic)
6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
6.7.1. Hospital Pharmacies
6.7.2. Gynaecology and Urology Clinics
6.7.3. Drug Stores
6.7.4. Retail Pharmacies
6.7.5. Online Drug Stores
6.8. Market Attractiveness Analysis
7. East Asia Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Drug Type
7.3.3. By Indication Type
7.3.4. By Distribution Channel
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
7.5.1. Penicillin & Combinations
7.5.2. Quinolones
7.5.3. Cephalosporin
7.5.4. Aminoglycoside Antibiotics
7.5.5. Sulphonamides
7.5.6. Azoles and Amphotericin B
7.5.7. Tetracycline
7.5.8. Nitrofurans
7.5.9. Other
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
7.6.1. Asymptomatic CAUTI (Bacteriuria)
7.6.2. Symptomatic CAUTI (Bacteremic)
7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
7.7.1. Hospital Pharmacies
7.7.2. Gynaecology and Urology Clinics
7.7.3. Drug Stores
7.7.4. Retail Pharmacies
7.7.5. Online Drug Stores
7.8. Market Attractiveness Analysis
8. South Asia & Pacific Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Drug Type
8.3.3. By Indication Type
8.3.4. By Distribution Channel
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Pacific
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
8.5.1. Penicillin & Combinations
8.5.2. Quinolones
8.5.3. Cephalosporin
8.5.4. Aminoglycoside Antibiotics
8.5.5. Sulphonamides
8.5.6. Azoles and Amphotericin B
8.5.7. Tetracycline
8.5.8. Nitrofurans
8.5.9. Other
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
8.6.1. Asymptomatic CAUTI (Bacteriuria)
8.6.2. Symptomatic CAUTI (Bacteremic)
8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
8.7.1. Hospital Pharmacies
8.7.2. Gynaecology and Urology Clinics
8.7.3. Drug Stores
8.7.4. Retail Pharmacies
8.7.5. Online Drug Stores
8.8. Market Attractiveness Analysis
9. Latin America Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Drug Type
9.3.3. By Indication Type
9.3.4. By Distribution Channel
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
9.5.1. Penicillin & Combinations
9.5.2. Quinolones
9.5.3. Cephalosporin
9.5.4. Aminoglycoside Antibiotics
9.5.5. Sulphonamides
9.5.6. Azoles and Amphotericin B
9.5.7. Tetracycline
9.5.8. Nitrofurans
9.5.9. Other
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
9.6.1. Asymptomatic CAUTI (Bacteriuria)
9.6.2. Symptomatic CAUTI (Bacteremic)
9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
9.7.1. Hospital Pharmacies
9.7.2. Gynaecology and Urology Clinics
9.7.3. Drug Stores
9.7.4. Retail Pharmacies
9.7.5. Online Drug Stores
9.8. Market Attractiveness Analysis
10. Middle East & Africa Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Indication Type
10.3.4. By Distribution Channel
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
10.5.1. Penicillin & Combinations
10.5.2. Quinolones
10.5.3. Cephalosporin
10.5.4. Aminoglycoside Antibiotics
10.5.5. Sulphonamides
10.5.6. Azoles and Amphotericin B
10.5.7. Tetracycline
10.5.8. Nitrofurans
10.5.9. Other
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
10.6.1. Asymptomatic CAUTI (Bacteriuria)
10.6.2. Symptomatic CAUTI (Bacteremic)
10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
10.7.1. Hospital Pharmacies
10.7.2. Gynaecology and Urology Clinics
10.7.3. Drug Stores
10.7.4. Retail Pharmacies
10.7.5. Online Drug Stores
10.8. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2022
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Quinolones
11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. Pfizer Inc.
11.3.1.1. Overview
11.3.1.2. Segments and Product
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. Merck & Co., Inc.
11.3.2.1. Overview
11.3.2.2. Segments and Product
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. GlaxoSmithKline (GSK)
11.3.3.1. Overview
11.3.3.2. Segments and Product
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. AstraZeneca
11.3.4.1. Overview
11.3.4.2. Segments and Product
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Bayer AG
11.3.5.1. Overview
11.3.5.2. Segments and Product
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Johnson & Johnson
11.3.6.1. Overview
11.3.6.2. Segments and Product
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. Novartis International AG
11.3.7.1. Overview
11.3.7.2. Segments and Product
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. Sanofi
11.3.8.1. Overview
11.3.8.2. Segments and Product
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Roche Holding AG
11.3.9.1. Overview
11.3.9.2. Segments and Product
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. Eli Lilly and Company
11.3.10.1. Overview
11.3.10.2. Segments and Product
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
11.3.11. Bristol-Myers Squibb Company
11.3.11.1. Overview
11.3.11.2. Segments and Product
11.3.11.3. Key Financials
11.3.11.4. Market Developments
11.3.11.5. Market Strategy
11.3.12. Abbott Laboratories
11.3.12.1. Overview
11.3.12.2. Segments and Product
11.3.12.3. Key Financials
11.3.12.4. Market Developments
11.3.12.5. Market Strategy
11.3.13. Astellas Pharma Inc.
11.3.13.1. Overview
11.3.13.2. Segments and Product
11.3.13.3. Key Financials
11.3.13.4. Market Developments
11.3.13.5. Market Strategy
11.3.14. Boehringer Ingelheim
11.3.14.1. Overview
11.3.14.2. Segments and Product
11.3.14.3. Key Financials
11.3.14.4. Market Developments
11.3.14.5. Market Strategy
11.3.15. Daiichi Sankyo Company, Limited
11.3.15.1. Overview
11.3.15.2. Segments and Product
11.3.15.3. Key Financials
11.3.15.4. Market Developments
11.3.15.5. Market Strategy
11.3.16. Gilead Sciences, Inc.
11.3.16.1. Overview
11.3.16.2. Segments and Product
11.3.16.3. Key Financials
11.3.16.4. Market Developments
11.3.16.5. Market Strategy
11.3.17. Mylan N.V.
11.3.17.1. Overview
11.3.17.2. Segments and Product
11.3.17.3. Key Financials
11.3.17.4. Market Developments
11.3.17.5. Market Strategy
11.3.18. Teva Pharmaceutical Industries Ltd.
11.3.18.1. Overview
11.3.18.2. Segments and Product
11.3.18.3. Key Financials
11.3.18.4. Market Developments
11.3.18.5. Market Strategy
11.3.19. Sun Pharmaceutical Industries Ltd.
11.3.19.1. Overview
11.3.19.2. Segments and Product
11.3.19.3. Key Financials
11.3.19.4. Market Developments
11.3.19.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
